This resistance mechanism has been demonstrated in various cell lines in vitro and validated in vivo using an athymic Nu/Nu mouse model, indicating the potent role of LINK-A in promoting drug resistance in breast cancer cells through the modulation of AKT pathway activity. Here, LINC01139 is linked to breast cancer.